CN102625842A - 用于输送生物活性rna的组合物和方法 - Google Patents

用于输送生物活性rna的组合物和方法 Download PDF

Info

Publication number
CN102625842A
CN102625842A CN2010800210226A CN201080021022A CN102625842A CN 102625842 A CN102625842 A CN 102625842A CN 2010800210226 A CN2010800210226 A CN 2010800210226A CN 201080021022 A CN201080021022 A CN 201080021022A CN 102625842 A CN102625842 A CN 102625842A
Authority
CN
China
Prior art keywords
sequence
rna
cell
biologically active
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800210226A
Other languages
English (en)
Chinese (zh)
Inventor
K.波拉科
J.费维尔
K.安沃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLSN LAB Inc
Original Assignee
Egen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egen Inc filed Critical Egen Inc
Publication of CN102625842A publication Critical patent/CN102625842A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN2010800210226A 2009-03-13 2010-03-15 用于输送生物活性rna的组合物和方法 Pending CN102625842A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16028809P 2009-03-13 2009-03-13
US16028709P 2009-03-13 2009-03-13
US61/160,288 2009-03-13
US61/160,287 2009-03-13
PCT/US2010/027365 WO2010105277A1 (en) 2009-03-13 2010-03-15 Compositions and methods for the delivery of biologically active rnas

Publications (1)

Publication Number Publication Date
CN102625842A true CN102625842A (zh) 2012-08-01

Family

ID=42728852

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800210226A Pending CN102625842A (zh) 2009-03-13 2010-03-15 用于输送生物活性rna的组合物和方法

Country Status (8)

Country Link
US (2) US8569065B2 (cg-RX-API-DMAC7.html)
EP (1) EP2406379A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012520085A (cg-RX-API-DMAC7.html)
KR (1) KR20110128345A (cg-RX-API-DMAC7.html)
CN (1) CN102625842A (cg-RX-API-DMAC7.html)
AU (1) AU2010223888A1 (cg-RX-API-DMAC7.html)
CA (1) CA2755245A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010105277A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525780B1 (en) 2010-01-19 2022-09-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
US20130101512A1 (en) * 2010-03-12 2013-04-25 Chad A. Mirkin Crosslinked polynucleotide structure
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012159164A1 (en) * 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013096958A1 (en) * 2011-12-23 2013-06-27 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
US20140371302A1 (en) * 2011-12-29 2014-12-18 Modema Therapeutics, Inc. Modified mrnas encoding cell-penetrating polypeptides
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
WO2014144423A2 (en) * 2013-03-15 2014-09-18 Techulon Inc. Antisense molecules for treatment of staphylococcus aureus infection
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
DK3184641T3 (da) 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
EP3105254B1 (en) * 2014-02-14 2019-11-20 Symvivo Corporation Hybrid proteins and uses thereof
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3183007B1 (en) 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
BR112017007012A2 (pt) 2014-10-06 2018-03-06 Exicure Inc compostos anti-tnf
US9816080B2 (en) * 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
AU2017212713B2 (en) 2016-01-27 2023-01-19 Oncorus, Inc. Oncolytic viral vectors and uses thereof
US11639371B2 (en) * 2016-02-17 2023-05-02 The Chinese University Of Hong Kong Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases
JP2019515654A (ja) 2016-03-16 2019-06-13 ザ ジェイ. デヴィッド グラッドストーン インスティテューツ 肥満及び/又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
MX2020000993A (es) 2017-07-26 2020-07-22 Oncorus Inc Vectores virales oncolíticos y usos de estos.
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
US20210139892A1 (en) * 2018-07-05 2021-05-13 The Regents Of The University Of California Compositions and methods for delivery of rna to a cell
EP4034088A4 (en) 2019-09-26 2023-10-11 President and Fellows of Harvard College Minimal arrestin domain containing protein 1 (arrdc1) constructs
WO2023244760A1 (en) * 2022-06-15 2023-12-21 Duke University Protein library display systems and methods thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060101A2 (en) * 2002-01-11 2003-07-24 University Of Southern California Gene delivery system and methods of use
CN1620464A (zh) * 2001-12-20 2005-05-25 遗传和生物技术工程中心 用于治疗人乳头状瘤病毒相关性癌症和其他上皮性肿瘤的肽
US20050260756A1 (en) * 2003-01-28 2005-11-24 Troy Carol M Complex for facilitating delivery of dsRNA into a cell and uses thereof
CN1940074A (zh) * 2006-08-07 2007-04-04 汪运山 胃癌靶向AFP基因的siRNAs表达载体的构建、筛选及其用途
WO2007126386A1 (en) * 2006-05-03 2007-11-08 Loetvall Jan Olof Exosome transfer of nucleic acids to cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof
WO2000039311A1 (en) * 1998-12-31 2000-07-06 Advanced Research And Technology Institute Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
AU2001294872A1 (en) 2000-09-28 2002-04-08 Cellomics, Inc. Methods and reagents for live-cell gene expression quantification
AU2003228301A1 (en) * 2002-03-06 2003-09-22 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of sirna molecules
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
EP1658304A4 (en) 2002-09-28 2009-01-14 Massachusetts Inst Technology THERAPY ANTIGRIPPALE
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
WO2007092222A2 (en) * 2006-02-02 2007-08-16 Regenetech, Inc. Method of characterizing a biologically active compound
JP2009532017A (ja) * 2006-02-10 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア PTD/CPPSへのdsRNA結合ドメイン融合体によるsiRNAの導入可能な送達
EP2631295A3 (en) * 2007-02-15 2014-01-01 DSM IP Assets B.V. A recombinant host cell for the production of a compound of interest
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1620464A (zh) * 2001-12-20 2005-05-25 遗传和生物技术工程中心 用于治疗人乳头状瘤病毒相关性癌症和其他上皮性肿瘤的肽
WO2003060101A2 (en) * 2002-01-11 2003-07-24 University Of Southern California Gene delivery system and methods of use
US20050260756A1 (en) * 2003-01-28 2005-11-24 Troy Carol M Complex for facilitating delivery of dsRNA into a cell and uses thereof
WO2007126386A1 (en) * 2006-05-03 2007-11-08 Loetvall Jan Olof Exosome transfer of nucleic acids to cells
CN1940074A (zh) * 2006-08-07 2007-04-04 汪运山 胃癌靶向AFP基因的siRNAs表达载体的构建、筛选及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAI等: "Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma", 《MOLECULAR THERAPY》 *

Also Published As

Publication number Publication date
US8569065B2 (en) 2013-10-29
JP2012520085A (ja) 2012-09-06
CA2755245A1 (en) 2010-09-16
KR20110128345A (ko) 2011-11-29
EP2406379A4 (en) 2012-09-26
WO2010105277A1 (en) 2010-09-16
US20140005254A1 (en) 2014-01-02
EP2406379A1 (en) 2012-01-18
US20100233141A1 (en) 2010-09-16
AU2010223888A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
US8569065B2 (en) Compositions and methods for the delivery of biologically active RNAs
JP7815327B2 (ja) フソソーム組成物およびその使用
JP2024099582A (ja) アルブミン遺伝子座からの導入遺伝子発現のための組成物及び方法
CA3120282A1 (en) Fusosome compositions for hematopoietic stem cell delivery
WO2021077000A1 (en) Engineered muscle targeting compositions
CA3120082A1 (en) Fusosome compositions for cns delivery
US20130164845A1 (en) Compositions and Methods for the Delivery of Biologically Active RNAs
WO2015002956A1 (en) Exosome delivery system
US20240408192A1 (en) Modified paramyxoviridae attachment glycoproteins
KR20230044420A (ko) 바이러스 푸소좀을 생산하기 위한 방법 및 조성물
WO2023115039A2 (en) Modified paramyxoviridae fusion glycoproteins
CA3120103A1 (en) Fusosome compositions for t cell delivery
WO2024064838A1 (en) Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
JP2024505678A (ja) 免疫療法のためのリンパ球活性化遺伝子3(lag3)組成物及び方法
EP4698665A1 (en) Engineered protein g fusogens and related lipid particles and methods thereof
TWI909459B (zh) 工程化噬菌體顆粒及使用該噬菌體顆粒進行基因治療的方法
WO2025011467A1 (zh) 工程化的哺乳动物基因写入系统
WO2024220574A1 (en) Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
JP2024526878A (ja) 調節されたウイルス送達システムおよびその使用
WO2023081926A1 (en) Delta protocadherin therapies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CLSN LABORATORIES, INC.

Free format text: FORMER OWNER: EGEN INC.

Effective date: 20150203

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150203

Address after: Delaware

Applicant after: CLSN LAB INC

Address before: alabama

Applicant before: Expression Genetics Inc.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120801